- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 92,710 | 09.07.24 08:20:01 | +0,200 | +0,22% | 92,710 | 92,830 | 92,710 | 92,510 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 970,200 | 09.07.24 08:03:31 | +10,000 | +1,04% | 967,200 | 978,600 | 970,200 | 960,200 |
